CRME Документы SEC - Cardiome Pharma Corp.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1036141

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cardiome Pharma Corp.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

June 9, 2020	15-12G	- 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-29338 Correvio Pharma Corp. (Exact name of registrant as specified in it
May 27, 2020	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on May 26, 2020 Registration Nos.
May 27, 2020	S-8 POS	- S-8 POS As filed with the Securities and Exchange Commission on May 26, 2020 Registration Nos.
May 27, 2020	EX-99.1	ADVANZ PHARMA Corp. Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp. Exhibit 99.1 ADVANZ PHARMA Corp. Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp. • Provides ADVANZ PHARMA with an immediate and direct commercial and medical presence in Germany, France, Spain, Italy, and the Benelux region, while strengthening its existing presence in the Nordics and the United Kingdom • Further diversifies ADVANZ PHARMA’s portfolio of medicin
May 27, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 27, 2020	POS AM	- POS AM As filed with the Securities and Exchange Commission on May 26, 2020 Registration No.
May 27, 2020	POS AM	- POS AM As filed with the Securities and Exchange Commission on May 26, 2020 Registration No.
May 27, 2020	F-10POS	- F-10POS As filed with the Securities and Exchange Commission on May 26, 2020 Registration Nos.
May 26, 2020	SC 13G/A	CRME / Cardiome Pharma Corp. / Klein Roger M. - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Correvio Pharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 2206V105 (CUSIP Number) 5/26/20 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
May 21, 2020	EX-99.1	;&S"V9VS-W9>Z)P/V9!S,/9Q[+ M/)G9G'DV\T)F begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH*-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3$R.#(U"B],96YG=&@Q(#0P,S$U-@HO5'EP92 O4W1R96%M M"CX^"G-T-''$9>F7P%0O1? O/)CW'\!KI=.KAE3/S8T[RJ R3D YMMF+FI:,O;P[=^! MX!N!Q?,O&B%/W66\"X(Y9, 3-?,63)WT:(&[T00@K, - USFY8O 3<$<'^8 M?C#-;5DUI^WC!]\#830>Y^V>;,677)WRK##!W%Y GKI\WNVG6GUIBAP'( MW?3X
May 21, 2020	EX-99.1	Correvio Obtains Final Order for Plan of Arrangement EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 21, 2020 Exhibit 99.1 Correvio Obtains Final Order for Plan of Arrangement NASDAQ: CORV TSX: CORV VANCOUVER, May 21, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme C
May 21, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 18, 2020	EX-99.2	CORREVIO PHARMA CORP. (the “Company”) Annual General and Special Meeting of Securityholders (the “Meeting”) May 15, 2020 REPORT OF VOTING RESULTS (Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations) Exhibit 99.2 CORREVIO PHARMA CORP. (the “Company”) Annual General and Special Meeting of Securityholders (the “Meeting”) May 15, 2020 REPORT OF VOTING RESULTS (Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations) Common Shares represented at the Meeting: 41,574,291 Total issued and outstanding Common Shares as at Record Date: 66,191,487 Percentage of issued a
May 18, 2020	EX-99.1	1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 15, 2020 Exhibit 99.1 1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV CORREVIO Announces Results from Annual GENERAL and special meeting of SECURITYHOLDERS Securityholders Approve ADVANZ PHARMA Acquisition VANCOUVER, CANADA – May 15, 2020 – Correvio Pharma Corp. (“Correvio” or the “Company”)
May 18, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 6, 2020	EX-99.1	Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 6, 2020 Exhibit 99.1 Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA NASDAQ: CORV TSX: CORV VANCOUVER, May 6, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a lead
May 6, 2020	EX-99.1	^('_F1[?)UD;SE0%LAB.4,N MQ7>K?$D>E)]HYVK3M&NTQ?C6:8]K;^BDZ[IE9.,K,588&\P]GDZ>$L]4[XO' M/C_>Y7C%\7="%$HG1]:$]H5^MB:8%T._E.IW4#I\O Y5K,P?OQ;<),?)R> MI1?ID.+U&R&%@1F?/R8#1D8M8%BB!B;X08@V\\OO/$1'Q58JJ8B>\:L5A< M)Y:(Z\5\4?UW8ZVW2\>%(_C>T+LP'= O"L^$I^ begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(V(# @;V)J#3P\+TQI;F5AF4@-C0O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8'H)(AD#P>1G$,G!F;W@F5;0"3+>1#); PFP;J87<&D$9CD!JM1 M +.S02076! , 'Y8F!@ M8&9@8 I@8 4R;C((,B" ( ,+4)2%@:,#R/E]L/G7H2\+&X#,F:T-$ 4N9J;G M6YP4-ZYK<5(S/2APX[J3 E!Q1P-#1T<'B,$ 9C8@:44"(E#,P)#&(,#0R[* M49U1CCF3Z2S3*J;[3&>8EC+M8F;EDF-@W==N>Y"!H?:)VG;-OQ"MO Q,OK. M-",0=P&Q -37#J$
May 6, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 4, 2020	EX-99.1	-R%!UI_; M'+#$LIT.5JI4B-BYB-,GA"GKALM9JL^+/5JF8#P)/.%(+S0_9TH1(,90V M8'5""U0%\!+2A%J_K0\$#8KBS X7R(2V-.NT7S8']S4FQ\IY-;GT[D DY MC0IX%RK'-AN?=6\V?%:F,%6APF(ZUZ#%#].?.NT:'&O@3J1M'P^#J:.426 MRP,KDVHB84''U@Q\E7B!(#] ?)0@MQ"["3)/ #2'"CY(9#XL_G_VO begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH*$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3$S-3,Q"B],96YG=&@Q(#0P-# X. HO5'EP92 O4W1R96%M M"CX^"G-T;UCE= )4.0"P=-F[L!#&Z[4X0-PT'LFDZM%U8T)SKP28E U@OG7&PL;%8S;?/@<$ MWW \OF;&A,["A?7>"2 $)P)HZNF]V BO,7S%IZ07Q8#P0FS%]0K1Y MT8S&Z55W*4$+%KH]-C^'V\+M0MG+6\4-\F-F!\SZ?E>T+AP MUJW?<&?0;R@&2"
May 4, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 4, 2020	EX-99.1	NASDAQ: CORV TSX: CORV EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 4, 2020 Exhibit 99.1 Correvio Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19 NASDAQ: CORV TSX: CORV VANCOUVER, May 4, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced tha
May 1, 2020	EX-99.1	6[R_^)\:)123O7:X$6Y#Z7M3-N5^T+NON"^T.]ROP@< M#.E&J3[R75=&1DFZ!8.=+V:3_[Q>+MHFRR$WLWV;P])1K)T[I)C5=)GUF MQN-D/B2!6O@XJIV 5TS8RX87O>NF([HZ'!$.R&G+4?8F+,E1\A!_^TSE6LQ M [J%3Z::#'94KR[6,#1(QGV6-3ZI%6PNHJHM'W>=SG9M3PT8]E7E [@"!=% M+G)H>>6A&8?H@)"I76 begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3$R-S(U"B],96YG=&@Q(#0P,S R- HO5'EP92 O4W1R96%M M"CX^"G-TY+?>FW/0(9";1@M-0$@0 M) D=@G0518D%2U!!UV5U=05[0=>;!#"@[XJ^NA94[&UW!14+[K+K[KKNNDKN M]YNY(19XQAXV3A7G.G6?FS,PY9\Z,L! +%\Q(3QD\3H]EM!O-T'Y-"G(R:=7?V0^ < MD-M5 )?CBK 4W#X9]YHZ9ODD9]M"5T
May 1, 2020	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 1, 2020	EX-99.1	NASDAQ: CORV TSX: CORV Exhibit 99.1 Leading Independent Proxy Advisory Firm ISS Recommends That Correvio Shareholders Vote for the Arrangement with ADVANZ PHARMA NASDAQ: CORV TSX: CORV VANCOUVER, May 1, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, released a rep
April 30, 2020	20-F	- 20-F 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 30, 2020	EX-13.1	Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as added by Section 906 of the Sarbanes – Oxley Act of 2002. EX-13.1 Exhibit 13.1 CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Correvio Pharma Corp. (the “Registrant”) filed under cover of Form 20-F for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Mark H. Corrigan as Chief Executive Officer of
April 30, 2020	EX-15.1	Consent of KPMG LLP. EX-15.1 9 d879645dex151.htm EX-15.1 Exhibit 15.1 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (604) 691-3000 Fax (604) 691-3031 Consent of Independent Registered Public Accounting Firm The Board of Directors Correvio Pharma Corp. We consent to the incorporation by reference in the registration statement (No. 333-225852) on Form F-10 and (No. 333-225015 and No. 33
April 30, 2020	EX-1.2	By-Law No. 1 of the Company, as amended. EX-1.2 Exhibit 1.2 BY-LAW NO. 1 OF CORREVIO PHARMA CORP. TABLE OF CONTENTS Part Page 1. INTERPRETATION 2 2. DIRECTORS 3 3. MEETING OF DIRECTORS 9 4. REMUNERATION OF DIRECTORS 11 5. SUBMISSION OF CONTRACTS OR TRANSACTIONS TO SHAREHOLDERS FOR APPROVAL 11 6. FOR THE PROTECTION OF DIRECTORS AND OFFICERS 11 7. INDEMNITIES TO DIRECTORS AND OFFICERS 12 8. OFFICERS 12 9. SHAREHOLDERS’ MEETINGS 14 10. SHAR
April 30, 2020	EX-12.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities and Exchange Act of 1934, as amended. EX-12.1 Exhibit 12.1 Certification of the Chief Executive Officer of Correvio Pharma Corp. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Mark H. Corrigan, certify that: 1. I have reviewed this annual report on Form 20-F of Correvio Pharma Corp. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
April 30, 2020	EX-1.1	Certificate of Incorporation, dated March 7, 2018, Certificate of Amendment of the Company dated March 15, 2018 and Certificate of Amendment of the Company dated May 11, 2018. EX-1.1 2 d879645dex11.htm EX-1.1 Exhibit 1.1 Innovation, Science and Innovation, Sciences et Economic Development Canada Développement économique Canada Corporations Canada Corporations Canada Certificate of Amendment Certificat de modification Canada Business Corporations Act Loi canadienne sur les sociétés par actions Correvio Pharma Corp. Corporate name / Dénomination sociale 1066955-5 Corporat
April 30, 2020	EX-4.4	Fourth Amending Agreement to Second Amended and Restated Term Loan Agreement between Correvio Pharma Corp. and CRG entered into on March 12, 2020. EX-4.4 Exhibit 4.4 FOURTH AMENDING AGREEMENT TO SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of March 12, 2020 between CORREVIO PHARMA CORP. as Borrower, The Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and CRG SERVICING LLC as Administrative and Collateral Agent - 2 - FOURTH AMENDING AGREEMENT TO THE SECOND AMENDED AND RESTATED TERM
April 30, 2020	EX-12.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities and Exchange Act of 1934, as amended. EX-12.2 Exhibit 12.2 Certification of the Chief Financial Officer of Correvio Pharma Corp. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Justin Renz, certify that: 1. I have reviewed this annual report on Form 20-F of Correvio Pharma Corp. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
April 17, 2020	EX-99.5	Voting Instruction Form Exhibit 99.5
April 17, 2020	EX-99.3	Form of Proxy Exhibit 99.3
April 17, 2020	EX-99.2	NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SECURITYHOLDERS MANAGEMENT INFORMATION CIRCULAR TO BE HELD ON MAY 15, 2020 DATED APRIL 7, 2020 Exhibit 99.2 These materials are important and require your immediate attention. If you have any questions or require more information with regard to the procedures for voting your shares or completing your transmittal documentation, please contact the proxy solicitation agent, Gryphon Advisors Inc. by telephone at 1.833.490.0586 toll-free in North America (1.416.661.6592 by collect call) or by em
April 17, 2020	EX-99.1	CORREVIO PHARMA CORP. 1441 Creekside Drive, 6th Floor Vancouver, B.C. V6J 4S7 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SECURITYHOLDERS Exhibit 99.1 CORREVIO PHARMA CORP. 1441 Creekside Drive, 6th Floor Vancouver, B.C. V6J 4S7 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SECURITYHOLDERS NOTICE IS HEREBY GIVEN that an annual general meeting of the holders (the “Shareholders”) of common shares (the “Shares”) of Correvio Pharma Corp. (“Correvio” or the “Company”) and a special meeting of the Shareholders, holders of options (the “
April 17, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of April 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
April 17, 2020	EX-99.4	Form of Proxy Exhibit 99.4
April 17, 2020	EX-99.6	Financial Statement Request Form Exhibit 99.6
April 17, 2020	EX-99.8	CORREVIO PHARMA CORP. (the “Company”) Exhibit 99.8 CORREVIO PHARMA CORP. (the “Company”) CERTIFICATE TO: British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Securities Commission Ontario Securities Commission Authorité des Marchés Financiers New Brunswick Financial and Consumer Services Commission Nova Scotia Securities Commission Prince Edward Isla
April 17, 2020	EX-99.7	LETTER OF TRANSMITTAL FOR SHARES OF CORREVIO PHARMA CORP. Pursuant to a proposed Plan of Arrangement involving CORREVIO PHARMA CORP. AND MERCURY PHARMA GROUP LIMITED EX-99.7 8 ex997.htm LETTER OF TRANSMITTAL Exhibit 99.7 A detailed description of the transactions described in this letter of transmittal (this “Letter of Transmittal”) is contained in the management information circular dated April 7, 2020 (the “Circular”) mailed to the holders (“Shareholders”) of common shares (“Shares”) of Correvio Pharma Corp. (“Correvio”) and certain other securityholders of
April 16, 2020	SC 13G	CRME / Cardiome Pharma Corp. / Klein Roger M. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Correvio Pharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 2206V105 (CUSIP Number) 4/13/20 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f
April 9, 2020	EX-99.1	NASDAQ: CORV TSX: CORV Exhibit 99.1 Correvio Obtains Interim Order For Plan Of Arrangement NASDAQ: CORV TSX: CORV VANCOUVER, April 8, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained an interim order from the Supreme Court of British Columbia (the "Court") authori
April 9, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of April 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
April 9, 2020	EX-99.1	!(5T$'NR8X/U&UC!BO@3TSV/FBEA3VS@_.UZ M_F&A0-R,(LE"K+T7I^3.B('5%W-UX6-M<4/"0:0N(-':1/;J!#7]^>X(DV MYHE\X8FLX3TD#<=#ACP\#'D\Y1(5(C-#9"!$O@R1C9),G9:0R8((@AG9;+GT M/W4[8I3<7=;:RGP9I$:Q/%>$^69\O&G %II#^#S^;[%SY7)F>Z,)/+!8 M9D\)_O_&?<2.#FJN^9Z672DT begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-34O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8#H.(AD#P.1G$,ER'DS6@DCF#6 U]\ B\F#V< M+6 UNT&D'5B$(1M(,NZI K/30&3E8A"I+@4DUM(,# !W; 0+,O 2#7R/P/C MT\\ 08 1[811PT96YD280VWW,[#N%F%@J+!5 MVZY%Z1G8%)/!E(,P)Q)\A"!B:U B?D0$@P #>=R .#0IE;F1S=')E86T- M96YD;V)J#3$Y(# @;V)J#3P\+TUE=&%D871A(#@@,"!2+U!A9V5,86)E;',@ M,30@,"!2+U!
March 30, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 30, 2020	EX-99.1	CORREVIO PHARMA CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2019 march 27, 2020 TABLE OF CONTENTS Exhibit 99.1 CORREVIO PHARMA CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2019 march 27, 2020 TABLE OF CONTENTS Page REFERENCE INFORMATION 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 CORPORATE STRUCTURE 7 GENERAL DEVELOPMENT OF THE BUSINESS 7 Three Year History 8 NARRATIVE DESCRIPTION OF THE BUSINESS 13 General 13 Summary of Our Products and Product Candidates 13 Our
March 30, 2020	EX-99.1	Form 51-102F3 MATERIAL CHANGE REPORT EX-99.1 5 ex994.htm MATERIAL CHANGE REPORT AND NEWS RELEASE DATED MARCH 30. 2020 Exhibit 99.4 Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer Correvio Pharma Corp. (“Correvio” or the “Corporation”, formerly known as Cardiome Pharma Corp.) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2. Date of Material Change March 30, 2020. Item 3. News Release Corr
March 30, 2020	EX-99.1	1441 Creekside Drive, 6th Floor Vancouver, B.C. V6J 4S7 Exhibit 99.1 1441 Creekside Drive, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV Correvio Reports full year 2019 FINANCIAL Results ADVANZ PHARMA to Acquire Correvio in a Deal Valued at US$76 Million Correvio to Hold a Meeting of Its Securityholders by No Later than May 20, 2020 Transaction Expected to Close During the Second Quarter of 2020 Vancouver,
March 30, 2020	EX-99.3	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.3 4 ex993.htm MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (“MD&A”) of Correvio Pharma Corp. (“Correvio”, the “Company”, “we”, “us” or “our”) for the year ended December
March 30, 2020	EX-99.5	Consent of Independent Registered Public Accounting Firm EX-99.5 6 ex995.htm CONSENT OF KPMG LLP Exhibit 99.5 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (604) 691-3000 Fax (604) 691-3031 Consent of Independent Registered Public Accounting Firm The Board of Directors Correvio Pharma Corp. We consent to the incorporation by reference in the registration statement (No. 333-225852) on Form F-10 and (No. 333-225015 and No
March 30, 2020	EX-99.1	D2GI";R(+(J"<228F H^W2#6+(.X1;<@^ M4Y1"M!:V\KM9D!T:X4+69(R97.8DT[016L0NS:1%U7=^Y/ISRJ)ZRQ^S[ M.4,N)Y?3RUS+F;$^L@-?3BWW_)UR(!9W<,A.\_K0.W]):Z-'N% /-3K]GR,P MR%HS#+V>T>GW+LY^KWT=SM8YR]CG;/WW7/T^./SYYF/^U^L] /EC2$[3_S_ M!^-N?.;%2W3M'Q3XM:5W+UN](]W_I begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C0W(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8-8 D0R!()+Q,XAD Y.,]2"2:0J(9#$&J0"DQ (B)@MC.8E :3 MM\#J-X)([A:PF=D@\B ;V+0D(,E8^1O$5I<"D7;J8#5A()+)#\KP T >BJ M?6!Q!D8ZD?\9FZ] P@P -]#$F8-"F5N9'-T8F!@8&9@8(ID8&5@X%W,(,B ((,+$!1%@:.&2#>GQ=-KP^>;J@Q M8' 2OFLZ+QS **,27'CNAHXT?U [email protected];[T4V.[6<-U^W3G=!=!369.N07A,]8!!!@ \<)$
March 30, 2020	EX-99.2	Report of Independent Registered Public Accounting Firm EX-99.2 3 ex992.htm AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 Exhibit 99.2 CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Consolidated Financial Statements For the years ended December 31, 2019, 2018 and 2017 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (604) 691-3000 Fax (604) 691-3031 Report of Independent Reg
March 30, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 23, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 23, 2020	EX-99.2	ADVANZ PHARMA CORP. LIMITED MERCURY PHARMA GROUP LIMITED CORREVIO PHARMA CORP. Exhibit 99.2 ADVANZ PHARMA CORP. LIMITED and MERCURY PHARMA GROUP LIMITED and CORREVIO PHARMA CORP. ARRANGEMENT AGREEMENT March 15, 2020 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 11 1.3 Number, Gender and Persons 12 1.4 Date for Any Action 12 1.5 Currency 12 1.6 Accounting Matters 12 1.7 Knowledge 12 1.8 Schedules 12 ARTICLE 2 THE ARRANGEMENT 13 2.1 Arrangem
March 23, 2020	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Correvio Pharma Corp. (the “Company” or “Correvio”) 1441 Creekside Dr, 6th Floor Vancouver, British Columbia V6J 4S7 Item 2: Dates of Material Change March 15, 2020 Item 3: News Release A news release announcing the material change was disseminated on March 16, 2020 through Newswire and a copy has been subsequent
March 18, 2020	EX-99.1	Date: March 17, 2020 Exhibit 99.1 Exhibit 99.1 Date: March 17, 2020 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: CORREVIO PHARMA CORP. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of M
March 18, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH 2020 Filed by e3 Filing, Computershare 1-800-973-3274 - CORREVIO PHARMA CORP. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2020 Commission File Number 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into Englis
March 16, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 16, 2020	EX-99.1	]:JJLS#U/S4U:HX[@6 MMI>DF/RQY.[Y$DULOG[1\89S&9B2$G)S+!MS=N5QVKR:$$>+ begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3$S.3,Q"B],96YG=&@Q(#0P-#8P- HO5'EP92 O4W1R96%M M"CX^"G-TN;,F3/SFV?FG@4( 'A02+"Q;NJ840NO:JH Q?@L M0-K6477U(RT;G2^"N,D,(%:,FC1QJAC?=CN(OQ@'9/\GHZ:>5?.@]^ \D#>6 M EQN'SMUVLC%N>"7!V'H#EICF+6Y9.6'5K&(0 YB?\ M>\Y%X-I+%3;ZI((3K +1-"UI6+ 4/A# +#^8%
March 16, 2020	EX-99.1	NASDAQ: CORV TSX: CORV Acquisition Expected to Have a Total Purchase Price of Approximately US$76 Million Including the Repayment of Certain Correvio Indebtedness ADVANZ PHARMA Intends to Pay for the Acquisition with Cash on Hand Provides ADVANZ PHAR EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 16, 2020 Exhibit 99.1 ADVANZ PHARMA to Acquire Correvio NASDAQ: CORV TSX: CORV Acquisition Expected to Have a Total Purchase Price of Approximately US$76 Million Including the Repayment of Certain Correvio Indebtedness ADVANZ PHARMA Intends to Pay for the Acquisition with Cash on Hand Provides ADVANZ PHARMA with an Immediate and Direct Commercial Presen
March 10, 2020	EX-99.1	Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 10, 2020 Exhibit 99.1 Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China NASDAQ: CORV TSX: CORV VANCOUVER and HONG KONG, March 10, 2020 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limi
March 10, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 10, 2020	EX-99.1	X&021#> #SJ.G[(O<;D@$&%M%[@_;4+A&1:9M<)/E(0NR%)F,GG$) M9-\6A/7BSB?L,&QOM2.[7\<+;1$)&B3PA2J+I)T[2KKZ)L/]752^N37_;V M8K40UA_SXFN$\=:ASX]@>&/Q/4O4W6)N&6CF=/\\:JX1S/0ATPN_&)]QGJ MH,EKJ2,1'CPWONOMZ9(Q,$<"HAA R!6(,0$#%NS>0H!Q66BBWB6464>KO=+! M5J[.- begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H)(AD#P>1G$,DJ!F:W@F5G@$@6+S#9#2:?@DCFM6!V)IB]!,R> M"F:!I%<+6 3\D#D\1\@DB$#2#+6!H/8&C(@TDX=2/Y7LF!@ KID*5@- R/5 MR/\,3"\ P08 .I5$E(-"F5N9'-TYO?'.)(8&#HZ #+<;0= MVD!00#5=#!(0+%'1P=<.1(0@6(&A@P& 89NEG6,LHP&S(^8E9EKF5V9&9EM MF'69FKED&-B.36!@J'FMML5VO^9OB%8N!B:'8"#-",3M0,S+P!
March 2, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 2, 2020	EX-99.1	Correvio Responds to Market Activity EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 2, 2020 Exhibit 99.1 Correvio Responds to Market Activity NASDAQ: CORV TSX: CORV VANCOUVER, March 2, 2020 /CNW/ - At the request of Investment Industry Regulatory Organization of Canada ("IIROC"), Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV) (the "Company") wishes to confirm that it is not aware of any material, undisclosed information related to th
March 2, 2020	EX-99.1	3[;%R=W-5J"5_)F"83R -^55- ME+KN%^G7P=%"5\9S_OBKOSNF16;C5I'BDG@@O&C;FIM_N1CY09Q"/5?NGWCK MU7=^=,^WN_\"G9N^IJJE^,#$$YVO#BP8'#L,U1LCC5AGG2C^_0G663@-(V:? MF3?)L%:1VN<%DF!#/_R 789>QHZH$JX/=0@3APX=!#G<$FAU"@KPLI;R;B\@ M?,E?:_8KE&K-?HTY,NO?B<2?W:>E#]5Z=\ begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AF4@-CDO5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8/X#(AD"0"3C9Q#)=@W,+@&13/U@$1\0R2H&%ID%%OD%)FW!XLE@ MT@XL8@-F+P"1W"T@DF4WV/PT(,FX/0)L8& X Y/H.)P]G^-4"0-3!Q PJ()(L (D( O%# Q1# (,,UEK M&4835DL>QA=&!=P/J8E9/E"9$!IYMQ@XBO(9^'*,&%A%LP(# @-C$R(#M]W+561>&E2I$L:U=REDK4? M7' 3WP%&QM4EYF9@V%0%+HG:H3@GV;W9V7YQF/T99QIAV37##MF10ITR
February 24, 2020	SC 13G	CORV / Correvio Pharma Corp. (Canada) / CLOUGH CAPITAL PARTNERS L P - SC 13G Passive Investment SC 13G CUSIP No. 22026V105 13G Page 1 of 9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Correvio Pharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 2206V105 (CUSIP Number) February 14, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru
January 28, 2020	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-3DO5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H/(AD#P.1G$,G#F9W@&6[P2(Z8'(WB&29#F8!9/U8)%C8'8G MF'T%1'U@$U( Y%58#,9LH$DX[X<,#L.1+J%@')E M9@T, T)25%3T8-"B @(" @(" @( T-3@@,"!O8FH-/#PO1FEL=&5R+T9L M871E1&5C;V1E+TD@,38X+TP@,34R+TQE;F=T:" Q-#4O4R X,3X^TR+%:='>BLJT":$8@[@9B+@2G+ M!L)GL@<(, #!:A\[#0IE;F1S=')E86T-96YD
January 28, 2020	EX-99.1	Correvio Receives NASDAQ Notification Regarding Deficiencies In Minimum Bid Price And Market Value Of Listed Securities Exhibit 99.1 Correvio Receives NASDAQ Notification Regarding Deficiencies In Minimum Bid Price And Market Value Of Listed Securities NASDAQ: CORV TSX: CORV VANCOUVER, Jan. 28, 2020 /CNW/ - Correvio Pharma Corp. (Nasdaq: CORV) (TSX: CORV), ("Correvio" or the "Company") announced today that it has received two written notifications from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company th
January 28, 2020	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of January 2020 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (A
January 7, 2020	SC 13G/A	CORV / Correvio Pharma Corp. (Canada) / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 19)* CORREVIO PHARMA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 22026V105 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
December 26, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of December 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
December 26, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of December 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
December 26, 2019	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Correvio Pharma Corp.
December 26, 2019	EX-99.1	1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 Exhibit 99.1 1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV Correvio Receives complete response letter from u.s. FDA for brinavess AND PROVIDES UPDATE ON RECENT EVENTS Vancouver, Canada, December 24, 2019 – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs,
December 19, 2019	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Correvio Pharma Corp. (“Correvio” or the “Company”) 1441 Creekside Drive, 6th Floor Vancouver, British Columbia Canada V6J 4S7 Item 2: Date of Material Changes December 10, 2019 and December 11, 2019 Item 3: News Release News releases announcing the material changes were issued on December 10, 2019 and December 1
December 19, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of December 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
December 11, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of December 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
December 11, 2019	EX-99.1	<$,J@2=.FLG&_%8%[PR0K5%9:7AQ MVU(DXB begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H)(AD#P>1G$,DJ"&9W@&4G@TB6C!Y%DRN ),?023S;C#[)YC\ M#B:Y0"1W"XADR :11XS!["0@R5B1#FK2X)(>W4@^5\CFH$)Z)E8#4,C%0C MS,PO?P,$& "R@24@T96YDV S$O Y/C3@B?,1X@ MP IB.P#0IE;F1S=')E86T-96YD;V)J#3(S(# @;V)J#3P\+TUE=&%D871A M(#$Q(# @4B]086=E3&%B96QS(#$X(# @4B]086=E%LP(# @-C$R(#%L
December 11, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Exhibit 99.1 Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 11, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced plans to explore strategic options to maximize stakeholder value. Potential strategic alternat
December 10, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of December 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
December 10, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of December 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
December 10, 2019	EX-99.1	AD1"ZQK[<)SY MF&86-HLF7B+^>/,47 5()'@.KS8+K5#MPACW/#)8 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8'H$(AD#P>1G$,G#F9W@&5;022++(AD+@&S%X+9AF!2$RSB!&9' M@LD&$,G= B(9LD'D@2=@TU* )&,-&XBM+@4B[=2 Y'\=H C0)4O!ZAD8J4;^ M9V!Z^1D@P M/@]2#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T, T M)25%3T8-"B @(" @(" @(" -"C4Y(# @;V)J#3P\+T9I;'1E,ZBW-RS \@MZ,#C#L:F#HZ&N"*D8 (%#,PI# (,/2S+&94851
December 10, 2019	EX-99.1	NASDAQ: CORV TSX: CORV EX-99.1 2 ex991.htm NEWS RELEASE DATED DECEMBER 10, 2019 Exhibit 99.1 Correvio Announces Outcome Of FDA Advisory Committee Meeting Reviewing Brinavess™ For The Treatment Of Recent Onset Atrial Fibrillation NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 10, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today anno
December 10, 2019	EX-99.1	DD/:27K"7K MR'JRF6PC#^#U;?)+JJ&I-(.&Z&+:15?1?GHKW4N/TX?I=^A%^@9]E_Z.F\V5 M<7W<'NX+OA[E(O):;:CQ0M3I7-15&4I9C?IOAV6RE"M0 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H$(AD#P>1G$,G*"V:W@65;021+,9A19>9@]F0^909B$@:<1LP27' MP'HXE8&A>HO:9MN#FG\A6KD8F.PK@#0C$+<#,20P4X0/F,A0( ! -N,)-P- M"F5N9'-T7!E+T-A=&%L;V<^ M/@UE;F1O8FH-,C0@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E M9$)O>%LP(# @-C$R(#%LP(# @-C$R(#7!E+U!A9V4^/@UE;F1O8FH-,C4@,"!O8FH-/#PO
December 10, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Exhibit 99.1 Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess™ For Recent Onset Atrial Fibrillation NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 10, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ and the Toronto Stock Exchange (TSX) have halted
November 25, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Exhibit 99.1 Correvio to Present at the Piper Jaffray 31st Annual Healthcare Conference NASDAQ: CORV TSX: CORV VANCOUVER, Nov. 25, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mark H.N. Corrigan, MD, Chief Executive Officer of Correvio, will present at the Piper Jaffray 31st Annual
November 25, 2019	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AF4@-3(O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8#H)(AD#P.1G$,G"6;W@&57@$B6AR"2>3F8G0EFSP&S$\'L C"I M!A;I!)%<+6 3P"KW58+9:4"2,?@6 <(@\61 M@ @4,S"D,0@P]+(L9E1C=&N9G9D9F8V8K-S,5T@%F92XZ!>9\P T-NJMIV MVX.:?R%:61@8/[\$THQ W G$[ Q,+!LA?,9\@ # )9'%LX-"F5N9'-T%LP(# @-C$R(#3K5]HO%V4U7F?3 M'!>U0;6,W'2[]-MC#+A: N*)Q.)9L2I M1@OBU
November 25, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 18, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Post Hoc Analysis of Subset of Patients Treated in the Emergency Department Setting Safety Outcomes of Interest Observed in Less Than 1% Cases; No Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Co EX-99.1 2 ex991.htm NEWS RELEASE DATED NOVEMBER 18, 2019 Exhibit 99.1 Correvio Announces Presentation of New Brinavess™ Spectrum Data at the American Heart Association 2019 Annual Meeting NASDAQ: CORV TSX: CORV Post Hoc Analysis of Subset of Patients Treated in the Emergency Department Setting Safety Outcomes of Interest Observed in Less Than 1% Cases; No Deaths Reported Greater Than 70% of Atrial
November 18, 2019	EX-99.1	-U'O$DL^GT>(C/I/[33/.7)-2N)(OI-YW=5A1UVWOU??K(SJKU$J^"@5 M?)0/AISN;:ZX08W=%.?ZW:0U]PR> begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(V(# @;V)J#3P\+TQI;F5AF4@-C8O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8'H (AD#P>1G$,G:!Q:?#!:I!XM< )',8#4L>6"V-Y@= F:[@LD@ M,!D (KE;0"1#-H@\I 5FIP%)QAHU$%M=&D3:@=CM98R, %=LALAH&1)N1 M!J;''P$"# " 5Q!4#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T, T M)25%3T8-"B @(" @(" @#0HV-2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O M9&4O22 Q.3$O3" Q-S4O3&5N9W1H(#$U,B]3
November 18, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 14, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 14, 2019	EX-99.2	CORREVIO PHARMA CORP. EX-99.2 3 ex992.htm CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Financial Statements Three and nine months ended September 30, 2019 and 2018 (Unaudited) CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Balance Sheets (In thousands of U.S. dollars, except share amounts) September 30, 2019 Decem
November 14, 2019	EX-99.3	Form 51-102F3 MATERIAL CHANGE REPORT EX-99.3 4 ex993.htm MATERIAL CHANGE REPORT DATED NOVEMBER 14, 2019 Exhibit 99.3 Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer Correvio Pharma Corp. (“Correvio” or the “Corporation”) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2. Date of Material Change November 14, 2019. Item 3. News Release Correvio issued a news release with respect to the mater
November 14, 2019	EX-99.4	Form 52-109F2 Certification of interim filings - full certificate EX-99.4 5 ex994.htm CERTIFICATE OF FILING - CEO Exhibit 99.4 Form 52-109F2 Certification of interim filings - full certificate I, Mark Corrigan, Chief Executive Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended Septem
November 14, 2019	EX-99.1	^[ZS:/EAID\_QE+TH Q[62ET;-B$U8 S>LMU&:TK;P;;M>[;OWTYM MW^$>[%0S!9[I[@<]D\)6 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C4V(# @;V)J#3P\+TQI;F5AF4@,3 Q+U1Y<&4O6%)E9B]76S$@,R Q73X^XQQ&YD;G!I%H M(#M[@PP']53,]:>@:GMR,F>SW%"25[BNAVCP T(X=??X'HZM[?4L.:%TG:S M8[O%SS5I%^=D;ZQYP<#1 00,$B!"J.C@0&(63I # :P!%@>0F):"V1(,##= MF@:DQ8!8%FQ&(, PUS6Y8QZC!8LPDR'F38Q'65Z":2?,SW@TF,0/?B/0:#F M'0,#7X':4=M+6KR,0O;1#!P, FT'&$V8VJ%^D&=@7OX!2#,"<1<0*S$P[RB& M\!E] (, ,;72+ -"F5N9'-T<@,"!O8FH-/#PO365
November 14, 2019	EX-99.1	NASDAQ: CORV TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November 14, 2019 at 8:30 a.m. Eastern (5: Exhibit 99.1 Correvio Reports Third Quarter 2019 Financial Results NASDAQ: CORV TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) VANCOUVER, Nov. 14, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CO
November 14, 2019	EX-99.5	Form 52-109F2 Certification of interim filings - full certificate Exhibit 99.5 Form 52-109F2 Certification of interim filings - full certificate I, Justin Renz, President and Chief Financial Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended September 30, 2019. 2. No misrepresentatio
November 14, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 14, 2019	EX-99.1	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.1 2 ex991.htm MANAGEMENT'S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (“MD&A”) of Correvio Pharma Corp. (“Correvio”, “we”, “us” or “our”) for the three and nine months ended September 30, 2019 is as of November 13, 2019. We have prepared this MD&A with reference to National
November 7, 2019	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5A%LP(# @-C$R(#%LP(# @-C$R(#7!E+T]B:E-T;3X^1!2 M.C@9VFUJ>ILER\#31I+,AR^]OOLXJ&]S-J\)<=E)D@8'3B4)-[%CNR1?=L M)ND(&C99)NO0[I@-U]N?X8E[9UL!^:0(.KD&P;+"?9M? S[ADLU^[<$R75;O.W^^ MNK>M[]^W== L0]F"MXE^>XJ%.N[%IQ(V"ATGIZTBHTW^;K!JL5:#(?5P[PG M5 (]Q:G85D'B[2(ZQ\4F2,"R4YUHX7.^#6PT2C\.IA\N\SK?5N63=I\4RP' MY7H3@+.L#=MO8,69Y)+EC92 G6Q:ZN:W>SSTB
November 7, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 7, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Conference Call Scheduled for Thursday, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) Exhibit 99.1 Correvio to Report Third Quarter 2019 Financial Results NASDAQ: CORV TSX: CORV Conference Call Scheduled for Thursday, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) VANCOUVER, Nov. 7, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it will report financial res
November 4, 2019	EX-99.1	<9B[ M1"I.'[C(7\]02:R begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H)(AD#P>1G$,G#&:W@V7[023+91#)7 (F(\$B.6!V!9AM#68W M@$EV$,G= B(9LD'DO@E@=AJ09PY!&K2X%(.W4@^5\?: 70)4O!:A@8J4;^ M9V!Z\1D@P #(G!!1#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T, T* M)25%3T8-"B @(" @(" @( T*-3D@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C M;V1E+TD@,3%LP(# @-C$R(#%LP(# @-C$R
November 4, 2019	EX-99.1	Correvio Announces FDA Advisory Committee Meeting to Review Brinavess™ for Recent Onset Atrial Fibrillation EX-99.1 2 ex991.htm NEWS RELEASE DATED NOVEMBER 4, 2019 Exhibit 99.1 Correvio Announces FDA Advisory Committee Meeting to Review Brinavess™ for Recent Onset Atrial Fibrillation NASDAQ: CORV TSX: CORV VANCOUVER, Nov. 4, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and D
November 4, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
September 27, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 correvio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of September 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, Brit
September 27, 2019	EX-99.1	Correvio to Present at the 2019 Cantor Global Healthcare Conference EX-99.1 2 ex991.htm NEWS RELEASE DATED SEPTEMBER 27, 2019 Exhibit 99.1 Correvio to Present at the 2019 Cantor Global Healthcare Conference NASDAQ: CORV TSX: CORV VANCOUVER, Sept. 27, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mark H.N. Corrigan, MD, Chief Executive Officer of Corr
September 27, 2019	EX-99.1	]4VLH$58(3/<;:4/'[N5[8>GWS.F_%_4=L=3NH(J5!TSQ9]_OP;$HA"M M%R"-L=*]6XS6V3@]YC\"# "+3C;4#0IE;F1S=')E86T-96YD;V)J#3(R(# @ M;V)J#3P\+T9I;'1E begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AF4@-3(O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8#H%(AD#P.1G$,GZ%0)S ],Y9D>FG\P\3,^99+CD&)AW&C,PY.Q0 MVVM[0O,O1"L+ ^/;9B#-",2=0,S.P/C/$,)GC <(, ,M!KL#0IE;F1S=')E M86T-96YD;V)J#3$U(# @;V)J#3P\+TUE=&%D871A(#4@,"!2+U!A9V5,86)E M;',@,3 @,"!2+U!A9V5S(#$R(# @4B]4>7!E+T-A=&%L;V<^/@UE;F1O8FH- M,38@,"!O8FH-/#PO07)T0F]X6S @," V,3(
September 12, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of September 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA
September 12, 2019	EX-99.1	Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application Exhibit 99.1 Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application NASDAQ: CORV TSX: CORV VANCOUVER, Sept. 12, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S. Food and Drug Administration (FDA) has accepted for review United Therapeutics Co
September 12, 2019	EX-99.1	3R\E3 0'^428B$->42,:Q#BQ MC%A-;"V$;N(FX@#Q,O-R[?OG%RQ8L.:FV_K[MM]?2S^0IU\825&6G2! /_ M@K+:EU'53!^U)E@NN'A>#"Y=>./>O5NN'!OZR+YJ\=JK')[EJTACS\ J^!?= MN$[RK]MWU;IU5^VCKHRR]E0N%XM>2>3?.EW/GWX=1XS)Y_/\Z\@M##'/'\: M%> begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH*$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3$Q-3@S"B],96YG=&@Q(#0P,38P- HO5'EP92 O4W1R96%M M"CX^"G-TPX0 /"@D&!=S>11(^9?TU . MBF@&2-TTHJ9VN&6=\U40?U8/():/F#!^LAC;?">(M]\9/G(R:?7?6(]^ < MD]9"? 3^^C)4X8OS%F@@"LPUS3QDR9//+SUSZ[ J!Z%X!UXOC)!46N19- M B"X,;YQ0O68*0UO7DIYA] ?]DY-6/KQX7G7P5
September 4, 2019	EX-99.1	Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference Exhibit 99.1 Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference NASDAQ: CORV TSX: CORV VANCOUVER, Sept. 4, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin Renz, President and Chief Financial Officer of Correvio, will present at the H.C. Wainwrigh
September 4, 2019	EX-99.1	?VE?A4WZAOS#?AB_HN^-[V7?9 M6%$W%ESR":Q-MX_S^7:BFDU/(V/GG\O5 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AJ(I/\S\#X^!M @ $ P$. M-PT96YD#"BZ2++,RX5@0>+#C#PV^ZX>J,Y1 RBA86!,?$%LP(# @-C$R(#IH'2H0%%2RM;FHBP:5$^G,2.II].8KA4- M96HM;ZMRD89FQFY'%VP:GALVWF2K,)RS[SI)8=G%.EO58"-"9V?E\ZQG MK(>>XM@MKK%S7/-YU%YDFWS]Z!#M;]/)-%JD316:Q2.[+JM-MHY;]VV%FG,V;K)UOA@4JW7 MBM,F;/[".1Z=+.D(5;YMRBH>F]"G[9]G)#1>:@PS+GZ4A'&U#%5>K$[&2X0B M;UY.V5U8Y753O9P,EN5#.&7ITW
September 4, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 correvio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of September 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, Brit
September 4, 2019	SC 13G/A	CORV / Correvio Pharma Corp. (Canada) / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 18)* CORREVIO PHARMA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 22026V105 (CUSIP Number) August 30, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
September 3, 2019	EX-99.1	Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes Exhibit 99.1 Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes NASDAQ: CORV TSX: CORV VANCOUVER, Sept. 3, 2019 /CNW/ - Correvio Pharma Cor
September 3, 2019	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C(O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H&(AD#P>1G$,G:#Q;O!8NT@T6>@D@6%C"Y$$RN 9',Z\#L'6#R M %C781#)W0(B&;)!Y!$?,#L-2#+6+ &QU55 I)T>D/RO]I&!">B2I6 U#(PT M(?\S,#[["!!@ #DT$U(-"F5N9'-TJ9YS%;,[LQ>S ',4>L; 4&VGMLVA.9?B%8N!B:O?"#-",3M0,S+P!2M".$S)@($& "7 M B+!#0IE;F1S=')E86T-96YD;V)J#3(S(# @;V)J#3P\+TUE=&%D871A(#$Q
September 3, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 correvio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of September 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, Brit
August 14, 2019	EX-99.1	FDA Accepts New Drug Application for BrinavessTM; PDUFA Date Set for December 24, 2019 Recently Strengthened Balance Sheet Extends Cash Runway Into Mid-2020 Management to Host Conference Call and Webcast Today, August 14, 2019 at 8:30 a.m. Eastern (5 Exhibit 99.1 Correvio Reports Second Quarter 2019 Financial Results FDA Accepts New Drug Application for BrinavessTM; PDUFA Date Set for December 24, 2019 Recently Strengthened Balance Sheet Extends Cash Runway Into Mid-2020 Management to Host Conference Call and Webcast Today, August 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, Aug. 14, 2019 /CNW/ - Correvio
August 14, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 14, 2019	EX-99.1	Y5DND1[ M>>\2[UKO'N\^[[->_5O>/WH_@1C%J]B8DA>'AM9,-_%- begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@.#8P-@HO3&5N9W1H,2 Q-#5GNJZE35K3IUZM2I^[401@AIT%Y$H:;& MM3[SH]7'T8(MT)I2=0UXCMW(?-"'&W0-E4]8)\;KS<<0,LT@1%?WC?0/ M/=&QW(V0(@[R-5OW=5WYHY'JQ&R\0A9?CG0V]7SROSZ[T!?;P#R!Z! 9V2 M!WV9()\X,#2Q,[>^C+DHP@Q;VP=[NYZDCTWC9#O(\AG#W7M'&'W61X?&)Q$/4A%)B0^"
August 14, 2019	EX-99.2	CORREVIO PHARMA CORP. EX-99.2 3 ex992.htm CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Financial Statements Three and six months ended June 30, 2019 and 2018 (Unaudited) CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Balance Sheets (In thousands of U.S. dollars, except share amounts) June 30, 2019 December 31, 201
August 14, 2019	EX-99.4	Form 52-109F2 Certification of interim filings - full certificate EX-99.4 5 ex994.htm CERTIFICATE OF FILING - CEO Exhibit 99.4 Form 52-109F2 Certification of interim filings - full certificate I, Mark Corrigan, Chief Executive Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended June 3
August 14, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 14, 2019	EX-99.5	Form 52-109F2 Certification of interim filings - full certificate EX-99.5 6 ex995.htm CERTIFICATE OF FILING - CFO Exhibit 99.5 Form 52-109F2 Certification of interim filings - full certificate I, Justin Renz, President and Chief Financial Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period
August 14, 2019	EX-99.3	Form 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.3 Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer Correvio Pharma Corp. (“Correvio” or the “Corporation”) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2. Date of Material Change August 14, 2019. Item 3. News Release Correvio issued a news release with respect to the material change on August 14, 2019. The news release was disseminated via
August 14, 2019	EX-99.1	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.1 2 ex991.htm MANAGEMENT'S DISCUSSION AND ANALYSIS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (“MD&A”) of Correvio Pharma Corp. (“Correvio”, “we”, “us” or “our”) for the three and six months ended June 30, 2019 is as of August 13, 2019. We have prepared this MD&A with reference to National Instrum
August 12, 2019	EX-99.1	<-H9 6S%@Q5]B&,XV0\NMRVK!6 MA)VK!7SF!VS11-!?OY.^"GZNH&U,E<(XGFYJGN)PP$+4EHK,?;80@R$NG M\7:3_-4\ Y@B5ZKV#N;6KDZP/[7J.D"YF>53'4U0[@#3 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8'H((AD#P>1G$,G#F8W@F7;023+Q#)W -F]X/9N6#V=# [%,C !7;(4K(:!D6KD M?P:F%Y\! @P RR$240T96YD7!E+T-A=&%L;V<^/@UE;F1O8FH-,C0@,"!O8FH-/#PO07)T0F]X6S @ M," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#%LP(# @-C$R(#7!E+U!A9V4^/@UE;F1O8FH-,C4@ M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9IT 0W'.
August 12, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 12, 2019	EX-99.1	Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress EX-99.1 2 ex991.htm NEWS RELEASE DATED AUGUST 12, 2019 Exhibit 99.1 Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress NASDAQ: CORV TSX: CORV VANCOUVER, Aug. 12, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that an abstract hig
August 9, 2019	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Correvio Pharma Corp. (“Correvio” or the “Company”) 1441 Creekside Drive, 6th Floor Vancouver, British Columbia Canada V6J 4S7 Item 2: Date of Material Change August 7, 2019 Item 3: News Release A news release announcing the material change was issued on August 7, 2019 through Canada Newswire and a copy was subse
August 9, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 8, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 8, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Conference Call Scheduled for Wednesday, August 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) Exhibit 99.1 Correvio to Report Second Quarter 2019 Financial Results NASDAQ: CORV TSX: CORV Conference Call Scheduled for Wednesday, August 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) VANCOUVER, Aug. 8, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it will report financial res
August 8, 2019	EX-99.1	<4^[#]27O, MSH_;)^TS=LYNUZ begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5A7!E+T-A=&%L;V<^/@UE;F1O8FH-,38@,"!O M8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#%LP(# @-C$R(#7!E+U!A M9V4^/@UE;F1O8FH-,3<@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I M!=SJ0J6PS/9IJ>H/!L M9@F^"U5U3+-V[FX.IN(67[?BNDV6^>CA;C^B5&VN\B+]6T+027B+.\B/>V-F&RR=8-=XUX,A]7]O*=, CTC MJ=G>0!+]@H.38I-KT('[1([/V387@XCX7#\X3RKLVU5KL2TS3;%
August 7, 2019	EX-99.1	Correvio Closes Public Offering of 9,200,000 Common Shares EX-99.1 2 ex991.htm NEWS RELEASE DATED AUGUST 7, 2019 Exhibit 99.1 Correvio Closes Public Offering of 9,200,000 Common Shares NASDAQ: CORV TSX: CORV VANCOUVER, Aug. 7, 2019 /CNW/ - Correvio Pharma Corp. (Nasdaq: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the closing of its previously announced underwritten public offering (the "
August 7, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 7, 2019	EX-99.1	6L;&>@8&3_5]J_K?3HD] 4R-- MC7\74WS9 !">D+^&/7 =_Z_+$(0>. ;0 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-38O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H(AD#P.1G$,G#F:W@F5[0"0+)XADK@>SMX#)PV"176#V93 9 M!A81 9%<+6 3LD'DP2XP.PE(,I8&@MCJRB#23@=(C< F@-TR40"% 5U3FS+',0F M35Q#)P'-1@82MZK';0]I<4(T%LP(# @-C$R(#ZZ4I0/*7AI3D!0DNK:?W\S=J!0Z&Z[)YT0>.P9V^.9>>8A$< AD2",@T2! M< :2!&2"@P;%-:"DC87$@A BA<2!D&B?I" 2Y4!S$!;7M0"1<@Y:@I3.
August 2, 2019	EX-99.1	1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 EX-99.1 2 tv526596ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV CORREVIO ANNOUNCES OVERNIGHT MARKETED OFFERING OF COMMON SHARES Vancouver, Canada, August 1, 2019 – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today
August 2, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2019 Commission File Number 000-29338 CORREVIO PHARMA CORP. (Translation of registrant's name into English) 1441 Creekside Drive, 6th Floor Vancouver, British Columbia, Canada V6J 4S7 (Add
August 2, 2019	EX-99.2	1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 EX-99.2 3 tv526596ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV CORREVIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES Vancouver, Canada, August 2, 2019 – Correvio Pharma Corp. (Nasdaq: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today
August 2, 2019	EX-99.3	COMMON SHARES CORREVIO PHARMA CORP. UNDERWRITING AGREEMENT EX-99.3 4 tv526596ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 COMMON SHARES CORREVIO PHARMA CORP. UNDERWRITING AGREEMENT August 2, 2019 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule I hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies/Gentlemen: Correvio Pharma Corp., a corporation organized and existing under the laws of Canada (the “C
August 2, 2019	SUPPL	CRME / Cardiome Pharma Corp. SUPPL - - SUPPL TABLE OF CONTENTS Filed pursuant to General Instruction II.L. of Form F-10 File No. 333-225852 PROSPECTUS SUPPLEMENT (To Base Shelf Prospectus dated July 5, 2018) CORREVIO PHARMA CORP. 8,000,000 Common Shares We are offering (the “Offering”) 8,000,000 Common Shares (the “Common Shares”) of Correvio Pharma Corp. (“Correvio” or the “Company”). Our Common Shares are listed on the Nasdaq Capital Ma
August 2, 2019	EX-99.1	Correvio Announces Pricing Of Public Offering Of Common Shares Exhibit 99.1 Correvio Announces Pricing Of Public Offering Of Common Shares NASDAQ: CORV TSX: CORV VANCOUVER, Aug. 2, 2019 /CNW/ - Correvio Pharma Corp. (Nasdaq: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the size and pricing of its previously announced underwritten public offering (the "Offering") of 8,000,000 common shares fro
August 2, 2019	EX-99.1	1#'\=/N[)@Q( /IC+HK[CCM)S M3#$2\28E6]PHMH@+Q-O$26AF".ZQ50Q14Q2F50&E4ZE5:E5I6@XE2,"JF2 M8F-#2@B!'B9!- %$X CF:-K $$S?A &SAU4,:$^?F:UA:N95XCY3#:J97]E7 M&JJ)B6.W]TT(U?2IZNZL[\?XVPV0ZV,>B&$TOQY$E!3M begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-38O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H((AD#P.1G$,G"F:W@V7!)(LEF%P#)K^"2.:]8/8E,/D+3,X$ MB^N"2X6L G9(/)@%YB=!"092W: V!JJ(-).!TC^US=@8 Z9"%(!B:N1 M!J;7GP$"# #K1Q)0#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T, T M)25%3T8-"B @(" @(" @#0HU-2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O M9&4O22 Q-C0O3" Q-#@O3&5N9W1H(#$S."]
August 2, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Ad
August 1, 2019	SUPPL	CRME / Cardiome Pharma Corp. SUPPL - - SUPPL TABLE OF CONTENTS Filed pursuant to General Instruction II.L. of Form F-10 File No. 333-225852 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement and accompanying base shelf prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such of
August 1, 2019	EX-99.1	"[J-1Z-O\CZ9 MZ/R4%![>%=OR: H\P<6CRVR_CZ8D;::\S/3RHS@F)UN3(MQ'+/8C:G+7N'' M/'Z<^,"U1=";5O begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-38O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H"(AD#P.1G$,G!6:W@V4[0"3+$Q#)[ LFP\$B]6"V'9B]!,RV M!)-:()[!40R9(/(@]9@TY* )&-I$8BMK@(B[;2!Y'^CV0Q,0)UG@ # +1J$%(-"F5N9'-T8FIM=,7YEEF>XP.S%=9SK! MI<3 >> F T.I@-HAVY-:C!"M[ Q,\CN!-(C;"<1<#$P&4R%\QCJ , S>,A M(PT*96YD%LP(# @-C$R(#%LP(# @ M-C$R(#7!E M+T]B:E-T;3X^0J^(5K%=.2"7
August 1, 2019	EX-99.1	Correvio Announces Overnight Marketed Offering of Common Shares EX-99.1 2 ex991.htm NEWS RELEASE DATED AUGUST 1, 2019 Exhibit 99.1 Correvio Announces Overnight Marketed Offering of Common Shares NASDAQ: CORV TSX: CORV VANCOUVER, Aug. 1, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has undertaken an overnight marketed underwritten public offer
August 1, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K 6-K 1 correvio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of August 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British
July 25, 2019	EX-99.1	O[;Y]8&JF$KA"6$=\6N4QVP;B)=N_<\=]_QYFQ+^^M;:!7_Y/ZM[OHPX MUF(,(ZZ%%I #&=WI2KMJ+C_#F9""#MF%.G8C begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AF4@-C(O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8'H$(AD#P>1G$,DZ 2Q>!Q:9 1:Y"R)9.,'D,A#)W QFGP&3F\#D M;K"X)8CD:@'KS0:11[:!2(8T(,E8>Q+$=M("D>K0/PC<&)J!+EH+5,##2 MA/S/P/3B(T" 0 P1-5#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T M, T)25%3T8-"B @(" @( T-C$@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C M;V1E+TD@,35BU&"48CEG+F MQ%LP M(# @-C
July 25, 2019	EX-99.1	NDA Seeks Approval for Brinavess for the Treatment of Recent Onset Atrial Fibrillation; PDUFA Date Set for December 24, 2019 Company Also Reports Certain Preliminary Financial Results for Second Quarter 2019 Exhibit 99.1 U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant) NASDAQ: CORV TSX: CORV NDA Seeks Approval for Brinavess for the Treatment of Recent Onset Atrial Fibrillation; PDUFA Date Set for December 24, 2019 Company Also Reports Certain Preliminary Financial Results for Second Quarter 2019 VANCOUVER, July 25, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: COR
July 25, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of July 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addr
June 24, 2019	EX-99.1	Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation Exhibit 99.1 Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation NASDAQ: CORV TSX: CORV VANCOUVER, June 24, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (
June 24, 2019	EX-99.1	TM4_[Q9EF@).+ $PW MS#]C;E?^ begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH*-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,3$S-#0U"B],96YG=&@Q(#0P,SDQ,@HO5'EP92 O4W1R96%M M"CX^"G-T" :5-!:JZT5K+=HW22 7V56JVW>(MM7T'%LZ6UK;7U(/O[ MSFR((+S'^''^R>%^3P[GYEG9I[GF6>>F<\VW@;CY5B '/QX^Z9SJ![V' MYH!\5J R^RC)DVN7YRS0 %%=S/N-77TY$DCGIG[A2 FKT U@GC)A44N99, MN@Q <&-X\B:T9.;WKC\
June 24, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of June 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addr
June 19, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of June 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addr
June 19, 2019	EX-99.1	Correvio Announces Voting Results Exhibit 99.1 Correvio Announces Voting Results NASDAQ: CORV TSX: CORV VANCOUVER, June 18, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 18, 2019. A total of 31,281,191 common shares were voted in connect
June 19, 2019	EX-99.1	ARKPV"!7I4+:U&Q600:;DL_P7 $E9BD]H+_$4&/!1#V0 ^PX#Y#)& M+FLNZRD;&/+O"]# P&[email protected]?;9-M>&[$Y2L_B_TP:-66+1S%H@Y>O)K(< MJCZ8YL&@,L% 44:FT begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AF4@-3(O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8#H+(AD#P.1G$,GZ&\SN!,O.!(O(@D@691#); 4FQ<'D23"I U;3 M!B:M021W"XADR 21^V^ V4E DC&/!<165P&1=B!=RU&9B +ID+5L/ 2#7R M/P/3A\\ 08 R%H040T96YDYE!C8]Y4Q M,.0N4CMD>TJ+$:*5A8&)^160!G$[@9B=@4DD L)G= <(, !O,!J3#0IE;F1S M=')E86T-96YD;V)J#3$U(# @;V)J#3P\+TUE=&%D871A(#4@,"!2+U!A9V5, M8
May 21, 2019	EX-99.5	CORREVIO PHARMA CORP. Exhibit 99.5 Exhibit 99.5 CORREVIO PHARMA CORP. + Please return completed form to: Computershare 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 ¨ Interim Financial Statements Mark this box if you would like to receive Interim Financial Statements by mail. ¨ Annual Financial Statements Mark this box if you would like to receive the Annual Financial Statements by mail. Financial Statement
May 21, 2019	EX-99.3	Proxies submitted must be received by 9:30 am, Vancouver Time, on Friday June 14, 2019. Exhibit 99.3 Exhibit 99.3 CORREVIO PHARMA CORP. 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on Tuesday, June 18, 2019 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their c
May 21, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K - Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY 2019 Filed by e3 Filing, Computershare 1-800-973-3274 - Correvio Pharma Corp. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2019 Commission File Number: 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English
May 21, 2019	EX-99.2	IMPORTANT INFORMATION FOR SHAREHOLDERS Notice of the Annual Meeting of Shareholders Information Circular May 9, 2019 Exhibit 99.2 Exhibit 99.2 IMPORTANT INFORMATION FOR SHAREHOLDERS Notice of the Annual Meeting of Shareholders and Information Circular May 9, 2019 TABLE OF CONTENTS INVITATION TO SHAREHOLDERS 1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS 2 INFORMATION CIRCULAR 3 VOTING AND PROXIES 3 BUSINESS OF THE MEETING 7 Background 7 Receipt of Financial Statements 7 Election of Directors 7 Appointment and Remune
May 21, 2019	EX-99.1	CORREVIO PHARMA CORP. 1441 Creekside Drive, 6th floor Vancouver, B.C. V6J 4S7 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS Exhibit 99.1 Exhibit 99.1 CORREVIO PHARMA CORP. 1441 Creekside Drive, 6th floor Vancouver, B.C. V6J 4S7 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO THE SHAREHOLDERS: NOTICE IS HEREBY GIVEN that an Annual Meeting (the “Meeting”) of the shareholders of CORREVIO PHARMA CORP. (the “Company”) will be held at the 6th Floor Boardroom, 1441 Creekside Drive, Vancouver, British Columbia, Canada, on June 18,
May 21, 2019	EX-99.4	VIFs submitted must be received by 9:30 am, Vancouver Time, on Friday, June 14, 2019 Exhibit 99.4 Exhibit 99.4 CORREVIO PHARMA CORP. 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Voting Instruction Form (“VIF”) - Annual General Meeting to be held on Tuesday, June 18, 2019 NON-REGISTERED (BENEFICIAL) SECURITYHOLDERS 1. We are sending to you the enclosed proxy-related materials that relate to a meeting of the hol
May 8, 2019	EX-99.1	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (“MD&A”) of Correvio Pharma Corp. (“Correvio”, “we”, “us” or “our”) for the three months ended March 31, 2019 is as of May 7, 2019. We have prepared this MD&A with reference to National Instrument 51-102 “Continuous Disclosure Obligations” of the Canadian Secur
May 8, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K Current Report of Foreign Issuer FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 8, 2019	EX-99.2	CORREVIO PHARMA CORP. Exhibit 99.2 CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Financial Statements Three months ended March 31, 2019 and 2018 (Unaudited) CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Balance Sheets (In thousands of U.S. dollars, except share amounts) March 31, 2019 December 31, 2018 Assets Current assets: Cash and cash equivalents $ 15,962
May 8, 2019	EX-99.4	Form 52-109F2 Certification of interim filings - full certificate Exhibit 99.4 Form 52-109F2 Certification of interim filings - full certificate I, Mark Corrigan, Chief Executive Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended March 31, 2019. 2. No misrepresentations: Based on my
May 8, 2019	EX-99.3	Form 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.3 Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer Correvio Pharma Corp. (“Correvio” or the “Corporation”, formerly known as Cardiome Pharma Corp.) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2. Date of Material Change May 8, 2019. Item 3. News Release Correvio issued a news release with respect to the material change on May 8, 2019. The n
May 8, 2019	EX-99.5	Form 52-109F2 Certification of interim filings - full certificate Exhibit 99.5 Form 52-109F2 Certification of interim filings - full certificate I, Justin Renz, President and Chief Financial Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended March 31, 2019. 2. No misrepresentations:
May 8, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K Current Report of Foreign Issuer FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Addre
May 8, 2019	EX-99.1	Mark H.N. Corrigan, MD Commences Role as CEO, effective March 14, 2019 Company on Track to Resubmit Brinavess NDA in Q2 2019 Management to Host Conference Call and Webcast Today, May 8, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) Exhibit 99.1 Correvio Reports First Quarter 2019 Financial Results Mark H.N. Corrigan, MD Commences Role as CEO, effective March 14, 2019 Company on Track to Resubmit Brinavess NDA in Q2 2019 Management to Host Conference Call and Webcast Today, May 8, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, May 8, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV
May 8, 2019	EX-99.1	1UD,>_0RTV8HBD%)>/$6#K#JEDWVH'^DO3NZ;VE]S.] M3_2>[V6;FU$KV]RZFNEN06U;^S?C@0U%^@%'"]& 56U#&[J_-YB7 E>!VIP: M!/ XT3_=/]-_IG^VGVWK'Z37M)86-D<2&QKEH64E9AS&!YMWDI;MS?40$? M-B(IK'G4".L$XL49E 0 PZAU2A4C)CE:.!4A0#(^DU:-:CJ'E^S?4I%1FXG MJ+<@#,:U:Y_,D8@_< begin 644 ex991.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@,C4T,S(+U1Y<&4@+U-T,"0A)#@3$AFLL)D#$E(%$CB,,EO(NF=6]TR MY,W,[W>'^^/]E,M4[=JENWMGO/\CWGGA+"""$EFD8TZNY:'0P?^'!W'"'< M#[5](V,;)K[S'\<-"/%@[JS(OVNFY\8>L,0H9NA)CF+1-;QYX;*O4@)/T2 M[-^Z=?3@%M]7\&%D.6S"&VMFWSADU7%M:^ M?Z&5!T&U2H==PB7$L/^[G; MQO8>4,
May 3, 2019	EX-99.1	Notice of meeting and record date for AGM on June 18, 2019 EX-99.1 2 exhibit99-1.htm NOTICE OF THE MEETING AND RECORD DATE Exhibit 99.1 Date: May 2, 2019 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: CORREVIO PHARMA CORP. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General
May 3, 2019	6-K/A	CRME / Cardiome Pharma Corp. 6-K/A Current Report of Foreign Issuer REPORT OF FOREIGN PRIVATE ISSUER DATED MAY 3, 2019 Filed by e3 Filing, Computershare 1-800-973-3274 - CORREVIO PHARMA CORP. - Form 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2019 Commission File Number 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into Engl
May 1, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K Current Report of Foreign Issuer FORM 6-K 6-K 1 correvio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of May 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Co
May 1, 2019	EX-99.1	Conference Call Scheduled for Wednesday, May 8, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) Exhibit 99.1 Correvio to Report First Quarter 2019 Financial Results on May 8, 2019 Conference Call Scheduled for Wednesday, May 8, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, May 1, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, announces that it will report financial
May 1, 2019	EX-99.1	NU0>[BJHM= M%P>YGU$G^0/LP/62R!^&=KC<+YK$$ H"(X\22J'@JZ_#I/)XN4G>EF53" M".(\X@J"!QF_(Q,]'/232B6+R.? begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AL>SB^!,8:E-7Y<# Y[V$ZRA8'180.09@3B3B!F9V ,E(;P&;T! M @P ,T 410T96YD%LP(# @-C$R(#%LP(# @-C$R(#^.]];"L%')0&81PH \(9 M4!8D#I4#F6A0'G2"@DD7(+F(+A7H 4(:S1H"<++!+0"R:V #Q8H%R5U72; MSP-]U):L<[;/#\UXVN0-"<930?Y0@$-)/EN=4;EI4#R;2?),XME,D]MV M:,A3JWE;E?-I:%)V.QRQ67AHV&2=+\,@8]]N[GZ$.9F9K-&+:"=TNRF;# ;] MO X+D-%?ABHWM ]7]4!!U<@V+2W^YQ> 7/)
April 12, 2019	EX-99.1	Date: April 12, 2019 EX-99.1 2 exhibit99-1.htm NOTICE OF MEETING AND RECORD DATE FOR AGSM ON JUNE 18, 2019 Exhibit 99.1 Date: April 12, 2019 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: CORREVIO PHARMA CORP. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meet
April 12, 2019	6-K	CRME / Cardiome Pharma Corp. REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF APRIL, 2019 (Current Report of Foreign Issuer) Filed by e3 Filing, Computershare 1-800-973-3274 - CORREVIO PHARMA CORP. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2019 Commission File Number 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into Englis
April 5, 2019	SC 13G/A	CORV / Correvio Pharma Corp. (Canada) / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 17)* CORREVIO PHARMA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 22026V105 (CUSIP Number) March 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
April 3, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of April 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
April 3, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Seven Data Abstracts Selected for Poster Presentations Exhibit 99.1 Correvio Announces Zevtera® Abstracts at ECCMID 2019 NASDAQ: CORV TSX: CORV Seven Data Abstracts Selected for Poster Presentations VANCOUVER, April 3, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that seven abstracts featuring Zevtera/Mabelio (ceftobiprole medocaril sodium),
April 3, 2019	EX-99.1	7!E+T]B:E-T;3X^ M begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5A/8S0( ! (. #2D-"F5N9'-T,C"L8I"2DN( I@ $N"#8@:&SR#:$/%(14.&06#MD,"["^DA%+2 MU+]7!E+T-A=&%L;V<^/@UE;F1O8FH- M,C0@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @ M-C$R(#%LP(# @-C$R M(#7!E+U!A9V4^/@UE;F1O8FH-,C4@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C M;V1E+T9I3WK&=MCSV\>PA%*)"7,PL (3%XRKY^^O9/ M,<7=[Y:,"!,6]/N/V=U@<)6OBQD1L0G$/DT(GGBW
April 3, 2019	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C,P(# @;V)J#3P\+TQI;F5A#8P,"P M)9'S4>2"O?:P:&?PL8&%=+;5RX< %'0P=' Q @RR(!/BAF8/@,HBT.U#FI M7!E+T-A=&%L M;V<^/@UE;F1O8FH-,S(@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]" M;&5E9$)O>%LP(# @-C$R(#%LP(# @-C$R(#7!E+U!A9V4^/@UE;F1O8FH-,S,@,"!O8FH-/#PO1FEL M=&5R+T9L871E1&5C;V1E+T9IWGT@BV^0SDO@='\#D]H[\DRTV.0C7 MA-/T/+ZFUX2=,4$G/]?Y\X%HN0[ZX;!W;EW].&[J^6::KVIB':>C;/T
April 3, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of April 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
April 3, 2019	EX-99.1	NASDAQ: CORV TSX: CORV Selected Data Abstracts for Presentation Exhibit 99.1 Correvio Announces Xydalba™ (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019 NASDAQ: CORV TSX: CORV Selected Data Abstracts for Presentation VANCOUVER, April 3, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Xydalba data abstracts will be presented at the 29th Europea
April 2, 2019	EX-99.1	25W5U?V_:NF08A(FS):HPJVB1ES M59V&RD?A?)7$;HIS&+XV6ABG7:6+:(:HD, 4&SMPOX-30X#E;=H:(K6Z?MC M#-S6'>U)?YNL%PF'A]G(T, JW2J.>Z!KW"KF!&CUJ,MBPOJQUR<>NWS"?,! MFK #&K'N .=X@0LEJ)X$V6X_/V9ON\^'>G6\HR#FA(!I8@ A $#EM"%@!6 M%,9K.F]W>%8>M=K_!7SO%J-'9.#._GGU+6 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AB,8^!G-^/ZP->@%1#.L M=PQO>L6JQNDC-&/1 09^VXKFH!TA8A M+ R,T9N -",0=P(Q.P-CC@J$S^@& M$& UV$8+@T96YD%LP(# @-C$R(#%LP(# @-C$R(#"@# CC0%D0 MSH!R('%'12!C#2H&HP5H#@X[SBK0$L0W,2@%0A-:PW"XN?3)S:LBJI.5MG, MTZQ9)S#8[//K^U-TF;M22X202Y0P%.);GL=ZKLD5QF@:/)$[3XZ;&O+4 M:3[4U2SQ[80]CY9ZM]:-EYF"S^98V? M@PS^IJCR]0&^9T7C<7('@B6#S3Y Z12Y:N5WX?.:M6
April 2, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of April 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
April 2, 2019	EX-99.1	Correvio to present at the H.C. Wainwright Global Life Sciences Conference Exhibit 99.1 Correvio to present at the H.C. Wainwright Global Life Sciences Conference NASDAQ: CORV TSX: CORV VANCOUVER, April 2, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin Renz, President and Chief Financial Officer of Correvio, will present at the H.C. Wainwright Global
March 20, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 20, 2019	EX-99.1	BM;>]PN:,09CX^DL#_+XNRM&!0>SOE> MK$/I'69+!\RR6?#&W!^;".C4O%G20[I)#TEQTT begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5A$8D);DR5'@>"CE#2- M+^>F0Y1R,3"\ ZD&8&X'8AY&1A^^4'XC,8 08 T[@4%LP(# @-C$R(#\7H##@N'$28'-!;6P+!'E0;:WCA6T% MMHI-[XS)&7+MG)S6P@41YPA.> 6+93#=#\B"$8* 9",4X: [".@=HAFS\.%#UBGY6KX MF(\+^E@;VI7!IVXW.WNJSH=57I'B?,C)#U2@,B7:#,HEQ6J1R/.R"72CT:" M(FB(E>B:,B+* 8'X@WJW(\+J[[/;C(!L53U5VNGY=-=1V$X.Q+/GTLI@3,A[X-VD"]F\^]C&:+8@W7Q?PJ5SDRS^# M[
March 20, 2019	EX-99.1	Data Will Also Be Presented at the Upcoming 23rd Israeli Congress for Emergency Medicine Exhibit 99.1 Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting Data Will Also Be Presented at the Upcoming 23rd Israeli Congress for Emergency Medicine NASDAQ: CORV TSX: CORV VANCOUVER, March 20, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, toda
March 18, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 18, 2019	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Correvio Pharma Corp. (“Correvio” or the “Company”) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2: Date of Material Change March 13, 2019 Item 3: News Release A news release announcing the material change was disseminated on March 14, 2019 through Canada Newswire and filed on SEDAR. Item 4: Summary
March 14, 2019	EX-99.2	CORREVIO PHARMA CORP. Common Shares Controlled Equity OfferingSM Sales Agreement Exhibit 99.2 CORREVIO PHARMA CORP. Common Shares Controlled Equity OfferingSM Sales Agreement March 13, 2019 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Correvio Pharma Corp., a corporation formed under the Canada Business Corporations Act (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issua
March 14, 2019	EX-99.1	CORREVIO ANNOUNCES AT THE MARKET OFFERING Exhibit 99.1 1441 Creekside Dr, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 FOR IMMEDIATE RELEASE NASDAQ: CORV TSX: CORV CORREVIO ANNOUNCES AT THE MARKET OFFERING Vancouver, Canada, March 14, 2019 — Correvio Pharma Corp. (Nasdaq: CORV) (TSX: CORV), (“Correvio” or the “Company”), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced
March 14, 2019	6-K	CRME / Cardiome Pharma Corp. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2019 Commission File Number 000-29338 CORREVIO PHARMA CORP. (Translation of registrant's name into English) 1441 Creekside Drive, 6th Floor Vancouver, British Columbia, Canada V6J 4S7 (Addr
March 14, 2019	SUPPL	CRME / Cardiome Pharma Corp. SUPPL SUPPL 1 tv516112suppl.htm SUPPL TABLE OF CONTENTS Filed Pursuant to General Instruction II.L of Form F-10 File No. 333-225852 PROSPECTUS SUPPLEMENT (To Base Shelf Prospectus dated July 5, 2018) New Issue March 13, 2019 CORREVIO PHARMA CORP. US$12,000,000 Common Shares We have entered into a Controlled Equity OfferingSM Sales Agreement dated March 13, 2019 (the “Sales Agreement”) with Cantor Fitz
March 13, 2019	EX-99.2	NASDAQ: CORV TSX: CORV Correvio Reports FOURTH Quarter and FULL YEAR 2018 FINANCIAL Results Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and W Exhibit 99.2 1441 Creekside Drive, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV Correvio Reports FOURTH Quarter and FULL YEAR 2018 FINANCIAL Results Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and Webcast Today, March 13, 2019 at 8:00 a.m. Eas
March 13, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 13, 2019	EX-99.1	Form 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer Correvio Pharma Corp. (“Correvio” or the “Corporation”, formerly known as Cardiome Pharma Corp.) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2. Date of Material Change March 13, 2019. Item 3. News Release Correvio issued a news release with respect to the material change on March 13, 2019.
March 13, 2019	EX-1.3	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 1.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (“MD&A”) of Correvio Pharma Corp. (“Correvio”, “we”, “us” or “our”) for the year ended December 31, 2018 is as of March 13, 2019. We have prepared this MD&A with reference to National Instrument 51-102 “Continuous Disclosure Obligations” of the Canadian Securiti
March 13, 2019	40-F	CRME / Cardiome Pharma Corp. 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13(A) OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission File Number 000-29338 CORREVIO PHARMA CORP. (Exact name of Registrant as specified
March 13, 2019	EX-1.1	CORREVIO PHARMA CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2018 MARCH 13, 2019 TABLE OF CONTENTS Exhibit 1.1 CORREVIO PHARMA CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2018 MARCH 13, 2019 TABLE OF CONTENTS Page REFERENCE INFORMATION 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 CORPORATE STRUCTURE 6 GENERAL DEVELOPMENT OF THE BUSINESS 7 Three Year History 7 NARRATIVE DESCRIPTION OF THE BUSINESS 10 General 10 Summary of Our Products and Product Candidates 11 Our S
March 13, 2019	EX-1.2	Report of Independent Registered Public Accounting Firm Exhibit 1.2 CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Consolidated Financial Statements For the years ended December 31, 2018 and 2017 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (604) 691-3000 Fax (604) 691-3031 Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors Correvio Pharma Corp.: Opinion on the C
March 11, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 11, 2019	EX-99.1	"^TDVC[6?J[]8OOE=F'WEDKLND:^YF-@;R)"GX3%0QX)N1- MM!(C[NU-I0PG7<,FREI9+QO=6K?>;11=DE^BDICG"IE%O[A:W"L^+EX08Z+D M%YM%2F!4 Z==0!-= L7FB(MG1/&X0B[.SU&.XHW5="M]B#Y'/Z8"-#2@,UHM M&J71/4KZ1QI+D&R)DPUQLCY.UL5) begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-38F)D M8!!@8&)@8+H,(AD#0"3#%A#)E@ 6:0;+UH%(%F,0R>P#9I>#V5/ [&5@L@LL M4@DF:T"DO0[8M&[email protected]=!"++ T$D5PN(5%<%DO\-%C,P 5VR$R&@9'* MY'\&IK>? (, 'L%$50-"F5N9'-T7!E+T-A=&%L;V<^ M/@UE;F1O8FH-,C @,"!O8FH-/#PO0V]N=&5N='-;,C0@,"!2(#(U(# @4B R M-B P(%(@,C<@,"!2(#(X(# @4B R.2 P(%(@,S @,"!2(#,Q(# @4ETO0W)O M<$)O>%LP(# @-C$R(#7!E+U!A9V4^ M/
March 11, 2019	EX-99.1	Amendment Provides for Up To an Additional $10 Million in Debt Funding Exhibit 99.1 Correvio Announces Amendment To Term Loan With CRG-Managed Funds Amendment Provides for Up To an Additional $10 Million in Debt Funding NASDAQ: CORV TSX: CORV VANCOUVER, March 11, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced an amendment to its existing agreement with CRG Se
March 7, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 7, 2019	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5AL#@;[O !C!#0IE;F1S=')E86T-96YD;V)J M#3$U(# @;V)J#3P\+TUE=&%D871A(#4@,"!2+U!A9V5,86)E;',@,3 @,"!2 M+U!A9V5S(#$R(# @4B]4>7!E+T-A=&%L;V<^/@UE;F1O8FH-,38@,"!O8FH- M/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#%LP(# @-C$R(#7!E+U!A9V4^ M/@UE;F1O8FH-,3<@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I'-@2'F";$VW8$]6KC]G7\=/[H%>1SEN%N#7J]
March 7, 2019	EX-99.1	Correvio to Present at Upcoming Investor Conferences EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 7, 2019 Exhibit 99.1 Correvio to Present at Upcoming Investor Conferences NASDAQ: CORV TSX: CORV VANCOUVER, March 7, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Correvio management will present at the following upcoming investor conferen
March 6, 2019	EX-99.1	G,^8O.[8VL-LS7-K8O-G<_J_ N?(YG<]<'YI<6@1^FMS^S& MY7E_ 0 GSJ6"[2'.80#?E^%>+\1U$T0&\J2"00G1JZBGCQ"-;-\47=%OR#H_ M"46,$XA#,E#/W$DHP7ZZA+.0QZ# I[I/1?;#X./LC5VX5C'8!G.IPWUU8/Z MW,W:XGR68W\$TP=Q3U.Q'P'AP8O"#QE'YW3%QE5\!.N0&VUL_W!N5Y"; X@& MK+<"T<3ZXZZ C^ begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5A!\R,#$RS 69Q\!(@/C/>/4G0( ! -^#!T-"F5N9'-TC@Z,#S$,"?%#,P/"9@9^!@6.+\ 3U"SX,,QOEF49=[$?\>D7 M]EK.%0-1S,+ J%0)I!F!N!.(V1D8C%LP(# @-C$R(#+Y8B)""!T"9-5%MM),2# RYQ!3:R'2G]^\ZL M#22!MFFU6F9W9O;L8?8, $1!2 M1G!^SD;ENJSB;;K(:%-;@N'PI=]GE\-)&[2A@36! P!G I";S-&9=%@^$D MD70%A9-$$WP;OJO19PU,W9W,69)]MRPZ29=9:,YN[]]^)$MZ.QT(P"IA /] MHQ-1Z-A6F=+
March 6, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of March 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (Add
March 6, 2019	EX-99.1	Conference Call Scheduled for Wednesday, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific) Exhibit 99.1 Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019 NASDAQ: CORV TSX: CORV Conference Call Scheduled for Wednesday, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific) VANCOUVER, March 6, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced t
February 21, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of February 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
February 21, 2019	EX-99.1	7)9GKSO7="R0F>:G;=H2]FT M,?);9IWD&%FGD5ET-(MZL_3UW?/E24%DE]!.U 5ZFZA'']3G_;+!AR<+1UP M1-?%B Y=UPSN299#H._Z8^LHQS!V:%,A->MFGQL&69=OR;P1X ! /I[[!<- M"F5N9'-T begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5A(T (1+T$ZMH%8V4""JP5(%!\% M$F&&0()O'@,3(\-<(, \ PPA#0IE;F1S=')E86T-96YD M;V)J#7-T87)T>')E9@T, T)25%3T8-"B @(" @(" @( T-#$@,"!O8FH- M/#PO1FEL=&5R+T9L871E1&5C;V1E+TD@,3(S+TP@,3 W+TQE;F=T:" Q,#@O M4R U-#X^$S S\# ]<400MU!Y<'K8W2C=^8VU@?^/3+:BT M%0-1S,+ J /I!F!N!.(V1D8#6H@?$9#@ # .MA$W(-"F5N9'-T%LP(# @-C$R(#!%H.EI!P^S&;L[7V\S&,9R7&9"R
February 21, 2019	EX-99.1	Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference Exhibit 99.1 Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference NASDAQ: CORV TSX: CORV VANCOUVER, Feb. 21, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Correvio's management team will participate in 1-on-1 meetings at the 8th Annual SVB Leerink Health
February 14, 2019	SC 13G	CORV / Correvio Pharma Corp. (Canada) / CLOUGH CAPITAL PARTNERS L P - SC 13G Passive Investment SC 13G CUSIP No. 22026V105 13G Page 1 of 9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Correvio Pharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 2206V105 (CUSIP Number) February 14, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru
February 13, 2019	SC 13G/A	CORV / Correvio Pharma Corp. (Canada) / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Correvio Pharma Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 22026V105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 7, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of February 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
February 7, 2019	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AX6($N M"23L5(%$(5 '(\-2D'D,C&00QG/? 4(, !AF LD#0IE;F1S=')E86T-96YD M;V)J#7-T87)T>')E9@T, T)25%3T8-"B @(" @(" @#0HU,2 P(&]B:@T\ M/"]&:6QT97(O1FQA=&5$96-O9&4O22 Q,S O3" Q,30O3&5N9W1H(#$Q,"]3 M(#8S/CYS=')E86T-"FC>8F!@8&9@8#)C8&%@X#S((," (,3$!1%@:.#0QK MGO.4<"YE8%C%("4EQ0$$, $DP ?%# R?0;[email protected]!(<9X0.I:2I M?3DU':4BX'A+8AF!.)V
February 7, 2019	EX-99.1	Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress Exhibit 99.1 Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress NASDAQ: CORV TSX: CORV VANCOUVER, Feb. 7, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlighting the low rate of h
January 25, 2019	SC 13G	CORV / Correvio Pharma Corp. (Canada) / SUMMER ROAD LLC - SCHEDULE 13 G FOR SUMMER ROAD LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CORREVIO PHARMA CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 22026V105 (CUSIP Number) January 16, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐
January 17, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of January 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (A
January 17, 2019	EX-99.1	;6_01.0 M\+Z"4-3=#G<#90$Q ;@9=#,;T8SWN9L $&(3@+K:Z ")E\#=?829_\= 8;T M"(7BZ)%]711M\9'\ML5Z>E,! begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5AF4@-38O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8+H.(AD#P.1G$,G#69W@&5[023+=+"X'9BM R;#P20#6'P>F!T M)BM )%<+B&3(!I'[0"8PVH%U,2:!R I3$FN!"3Z[ Q, %=LA"LGH&1:N1 M!J8WGP$"# MD ]1#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T, T* M)25%3T8-"B @(" @(" @( T*-34@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C M;V1E+TD@,38T+TP@,30X+TQE;F=T:" Q-#,O4
January 17, 2019	EX-99.1	Correvio Provides Update On At The Market Offering Exhibit 99.1 Correvio Provides Update On At The Market Offering NASDAQ: CORV TSX: CORV VANCOUVER, Jan. 17, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the completion of sales of all common shares qualified under its ATM Prospectus Supplement (defined below). The Comp
January 12, 2019	EX-99.1	Form 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 Form 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Correvio Pharma Corp. (“Correvio” or the “Company”) 1441 Creekside Dr. 6th floor Vancouver, BC V6J 4S7 Item 2 Date of Material Change January 1, 2019 Item 3 News Release Correvio issued a news release with respect to the material change on January 2, 2019. The news release was disseminated via PR Newsire and subse
January 12, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of January 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (A
January 2, 2019	EX-99.1	C M)D/$!%W(7P\;X![X/CP!3\-KA",N"$ S],$ ;(,[H0-;=".?<4>QOQ>>(P%R M&0@LP%%&B8.LYG9@C_OA->P]C/II@AY8BW,\AGVB\ -LGTV:R1ODC5S.=P# M4 M$,:9M\.]\!"V>T0>>PP^@_]#]7RCL%,X#G9P0QKDH:SS<9X^E' KW Z[ M8!_\$%Z'SXF2J(B+N,DP^9C\A1KH3?0 5\UK^+=0+@H>[#L;@CA+&%=W'&Z& begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AL,#L8I2D.( )H $^*"8@>$SB+9HF,[DQ%LP(# @-C$R(#%LP(# @-C$R(#7!E+T]B:E-T;3X^7(B6V\ ?#GOW5KMO+]MZN9GFXI8Q^DXV[[/B^5C11B]RL/Z0'!-)ZML MN2?.^G\U&I5/]X,$#F0#)PEP7F<"?G@N9-L7:R^S$KUOF>W.7D4E.MO\ MZ7EWV3JGG@,,OSY-!S=5MBKFMS,OD5:[O)HTKMRM\Y6?NESL"AAC ;1R\UR ME9,!5S2M\O7?Q/ +D]1WQ UH^:[85N6.?JFODQCG[XJ'$6>-^+=9EXNBLV2 M?BXVEYM]<9A/BMV^&C]F.R)
January 2, 2019	EX-99.1	– Mark H.N. Corrigan, MD to Succeed William Hunter, MD as Chief Executive Officer by the End of the First Quarter 2019 – – Dr. Hunter to Remain a Member of the Board of Directors – – Chief Financial Officer, Justin Renz, Appointed President – – Vanda Exhibit 99.1 Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes NASDAQ: CORV TSX: CORV – Mark H.N. Corrigan, MD to Succeed William Hunter, MD as Chief Executive Officer by the End of the First Quarter 2019 – – Dr. Hunter to Remain a Member of the Board of Directors – – Chief Financial Officer, Justin Renz, Appointed President – – Vanda De Cian, MD, to
January 2, 2019	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of January 2019 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (A
November 20, 2018	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2018 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 20, 2018	EX-99.1	Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference Exhibit 99.1 Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference NASDAQ: CORV TSX: CORV VANCOUVER, Nov. 20, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Dr. William Hunter, President and Chief Executive Officer of Correvio, will present at
November 20, 2018	EX-99.1	EX-99.1 begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$T(# @;V)J#3P\+TQI;F5A @08 -.K#"D-"F5N9'-T%LP(# @-C$R(#%LP(# @-C$R(#/W8&LS#R <20 M"<31B+Y:J[C)FW0YSKFF+LUSJR 5V2"P XY)$8?I6-)BY%1TF;8/NZVH= M^V9)[]-:.?&CHOTHV?KNBGN\^C6N."\@"VL#1J,EG4^GDW3G'X@PJ%PM M:>RW:9TV657229ZN^LA],(#K#&W3WYDN8[#\(MX30>=YQ+6%OF*#)MZT M;(U6V]8^&D'L>+?V94.=;RY4PDL[R=+,C4H1SF$RJ MI^45A\U?26;A HPDD3.K8)QEN8?#=^$T4+%("TB^6$QN[OZZAHT45
November 6, 2018	EX-99.1	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management discussion and analysis (“MD&A”) of Correvio Pharma Corp. (“Correvio”, “we”, “us” or “our”) for the three and nine-month periods ended September 30, 2018 is as of November 5, 2018. We have prepared this MD&A with reference to National Instrument 51-102 “Continuous Disclosure Obligatio
November 6, 2018	EX-99.3	Form 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.3 Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer Correvio Pharma Corp. (“Correvio” or the “Corporation”, formerly known as Cardiome Pharma Corp.) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7 Item 2. Date of Material Change November 6, 2018 Item 3. News Release Correvio issued a news release with respect to the material change on November 6, 20
November 6, 2018	EX-99.5	Form 52-109F2 Certification of interim filings - full certificate EX-99.5 6 ex995.htm CERTIFICATE OF FILING - CFO Exhibit 99.5 Form 52-109F2 Certification of interim filings - full certificate I, Justin Renz, Chief Financial Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended Septembe
November 6, 2018	EX-99.2	CORREVIO PHARMA CORP. Exhibit 99.2 CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Financial Statements Three and nine months ended September 30, 2018 and 2017 (Unaudited) CORREVIO PHARMA CORP. (formerly Cardiome Pharma Corp.) Interim Consolidated Balance Sheets (Note 1) (Expressed in thousands of U.S. dollars, except share amounts) September 30, 2018 December 31, 2017 Assets Current assets:
November 6, 2018	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2018 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
November 6, 2018	EX-99.4	Form 52-109F2 Certification of interim filings - full certificate Exhibit 99.4 Form 52-109F2 Certification of interim filings - full certificate I, William Hunter, President and Chief Executive Officer of Correvio Pharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Correvio Pharma Corp. (the “issuer”) for the interim period ended September 30, 2018. 2. No misrepresenta
November 6, 2018	EX-99.1	NASDAQ: CORV TSX: CORV Correvio Reports THird Quarter 2018 FINANCIAL Results Management to Host Conference Call and Webcast Today, November 6, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific) Exhibit 99.1 1441 Creekside Drive, 6th Floor Vancouver, B.C. V6J 4S7 Tel: 604-677-6905 Fax: 604-677-6915 NASDAQ: CORV TSX: CORV Correvio Reports THird Quarter 2018 FINANCIAL Results Management to Host Conference Call and Webcast Today, November 6, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific) Vancouver, Canada, November 6, 2018 - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generati
November 6, 2018	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of November 2018 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (
October 30, 2018	EX-99.1	Conference Call Scheduled for Tuesday, November 6, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific) Exhibit 99.1 Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018 Conference Call Scheduled for Tuesday, November 6, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, Oct. 30, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today anno
October 30, 2018	6-K	CRME / Cardiome Pharma Corp. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13A-16 or 15d-16 of The Securities Exchange Act of 1934 For the month of October 2018 COMMISSION FILE Number. 000-29338 CORREVIO PHARMA CORP. (Translation of registrant’s name into English) 1441 Creekside Drive, 6th floor Vancouver, British Columbia, V6J 4S7, CANADA (A

CRME / Cardiome Pharma Corp. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)